This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/domain/vavai/projekt/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023752%3A_____%2F12%3A43913773%21RIV13-MZ0-00023752/
n12http://linked.opendata.cz/resource/domain/vavai/subjekt/
n10http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n17http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023752%3A_____%2F12%3A43913773%21RIV13-MZ0-00023752
rdf:type
n10:Vysledek skos:Concept
rdfs:seeAlso
http://www.hdbp.org/psychiatria_danubina/pdf/dnb_vol24_sup1/dnb_vol24_sup1_153.pdf
dcterms:description
Background: Inflammatory immune processes have been clearly implicated in the etiopathology of schizophrenia. There are, however, only limited data dealing with immune parameters in the first episode patients with schizophrenia and the course of these parameters during treatment. Subjects and Methods: The presented study compared plasma levels of interleukin (IL)-6, IL-8, IL-10 and TNF-alpha in 25 patients with the first episode of schizophrenia with the minimal exposition of antipsychotics before and after treatment and with age and sex matched group of healthy volunteers. Changes in plasma cytokine levels were investigated after 4 weeks of treatment in relationship with the therapeutic outcome. Results: Our results show significantly increased plasma levels of IL-6 (p <= 0.001) and TNF-alpha (p <= 0.001) in patients at the admission in comparison with healthy volunteers. After 4 weeks of the treatment the PANSS score decreased (p <= 0.001), concurrently the plasma level of IL-6 decreased and TNF-alpha did not show any decrease after treatment. The patients' posttreatment and healthy control group comparison showed higher plasma levels of TNF-alpha (p=0.008) and marginally elevated plasma level of IL-6 (p=0.046) in the posttreatment group. Plasma levels of IL-8 and IL-10 did not show any significant differences. Conclusions: Our study validated the presence of the proinflammatory state in the first episode of schizophrenia. IL-6 may be considered as a state marker for acute exacerbations and TNF-alpha may be a trait marker of schizophrenia. Background: Inflammatory immune processes have been clearly implicated in the etiopathology of schizophrenia. There are, however, only limited data dealing with immune parameters in the first episode patients with schizophrenia and the course of these parameters during treatment. Subjects and Methods: The presented study compared plasma levels of interleukin (IL)-6, IL-8, IL-10 and TNF-alpha in 25 patients with the first episode of schizophrenia with the minimal exposition of antipsychotics before and after treatment and with age and sex matched group of healthy volunteers. Changes in plasma cytokine levels were investigated after 4 weeks of treatment in relationship with the therapeutic outcome. Results: Our results show significantly increased plasma levels of IL-6 (p <= 0.001) and TNF-alpha (p <= 0.001) in patients at the admission in comparison with healthy volunteers. After 4 weeks of the treatment the PANSS score decreased (p <= 0.001), concurrently the plasma level of IL-6 decreased and TNF-alpha did not show any decrease after treatment. The patients' posttreatment and healthy control group comparison showed higher plasma levels of TNF-alpha (p=0.008) and marginally elevated plasma level of IL-6 (p=0.046) in the posttreatment group. Plasma levels of IL-8 and IL-10 did not show any significant differences. Conclusions: Our study validated the presence of the proinflammatory state in the first episode of schizophrenia. IL-6 may be considered as a state marker for acute exacerbations and TNF-alpha may be a trait marker of schizophrenia.
dcterms:title
Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls
skos:prefLabel
Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls
skos:notation
RIV/00023752:_____/12:43913773!RIV13-MZ0-00023752
n10:predkladatel
n12:ico%3A00023752
n4:aktivita
n8:P n8:I
n4:aktivity
I, P(NT13843)
n4:cisloPeriodika
Suppl.1
n4:dodaniDat
n17:2013
n4:domaciTvurceVysledku
n6:7625952 n6:6339824
n4:druhVysledku
n9:J
n4:duvernostUdaju
n13:S
n4:entitaPredkladatele
n15:predkladatel
n4:idSjednocenehoVysledku
141110
n4:idVysledku
RIV/00023752:_____/12:43913773
n4:jazykVysledku
n18:eng
n4:klicovaSlova
alpha; TNF; interleukin (IL) -6; inflammation; schizophrenia
n4:klicoveSlovo
n5:TNF n5:alpha n5:schizophrenia n5:inflammation n5:interleukin%20%28IL%29%20-6
n4:kodStatuVydavatele
HR - Chorvatská republika
n4:kontrolniKodProRIV
[2C8E5658341D]
n4:nazevZdroje
Psychiatria Danubina
n4:obor
n11:FL
n4:pocetDomacichTvurcuVysledku
2
n4:pocetTvurcuVysledku
3
n4:projekt
n14:NT13843
n4:rokUplatneniVysledku
n17:2012
n4:svazekPeriodika
24
n4:tvurceVysledku
Novák, Tomáš Kubištová, Alžběta Horáček, Jiří
n4:wos
000309094600035
s:issn
0353-5053
s:numberOfPages
4